About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

COMPLETEDPhase 3

Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants

Immunogenicity Study of a DTaP IPV Hep B PRP T Combined Vaccine in Comparison to Infanrix Hexa™, Both Concomitantly Administered With Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants

NCT00401531•Sanofi Pasteur, a Sanofi Company

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Hepatitis BPolioDiphtheria+2 more

Interventions

DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines

DTaP-HB-IPV and Pneumococcal polysaccharide vaccines

Locations

2

Thailand

Locations (2)

Bangkok, Thailand

Khonkaen, Thailand

Key Dates

Start Date

October 1, 2006

Primary Completion Date

November 1, 2007

Completion Date

August 1, 2008

Last Updated

April 1, 2014

Related Studies

RECRUITINGPhase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

NCT07024641

Hepatitis B Virus Infection

RECRUITINGPhase 2

Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

NCT05644184

RECRUITINGPhase 1

Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B

NCT06671093

Chronic Hep BChronic Hepatitis b+2 more

RECRUITINGPhase 1

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

NCT07203755

Diphtheria, Tetanus and Acellular PertussisEpidemic Meningitis+1 more

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

NCT07275554

HBV Related Acute-on-chronic Liver FailureHBV-related Liver Cirrhosis+1 more

RECRUITINGPhase 1

hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

NCT03826433

View all related studies

Sponsors

Lead Sponsor

Sanofi Pasteur, a Sanofi Company

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 1, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions